1.
|
Vaughan S, Coward JI, Bast RC Jr, et al:
Rethinking ovarian cancer: recommendations for improving outcomes.
Nat Rev Cancer. 23:719–725. 2011. View
Article : Google Scholar
|
2.
|
Köbel M, Kalloger SE, Boyd N, et al:
Ovarian carcinoma subtypes are different diseases: implications for
biomarker studies. PLoS Med. 5:e2322008.PubMed/NCBI
|
3.
|
Swenerton KD, Santos JL, Gilks CB, et al:
Histotype predicts the curative potential of radiotherapy: the
example of ovarian cancers. Ann Oncol. 22:341–347. 2010. View Article : Google Scholar : PubMed/NCBI
|
4.
|
Gilks CB, Ionescu DN, Kalloger SE, et al:
Tumor cell type can be reproducibly diagnosed and is of independent
prognostic significance in patients with maximally debulked ovarian
carcinoma. Hum Pathol. 39:1239–1251. 2008. View Article : Google Scholar : PubMed/NCBI
|
5.
|
Anglesio MS, Carey MS, Köbel M, et al:
Clear cell carcinoma of the ovary: A report from the first Ovarian
Clear Cell Symposium, June 24th, 2010 (Review). Gynecol Oncol.
121:407–415. 2010. View Article : Google Scholar : PubMed/NCBI
|
6.
|
Takakura S, Takano M, Takahashi F, et al
Japanese Gynecologic Oncology Group: Randomized phase II trial of
paclitaxel plus carboplatin therapy versus irinotecan plus
cisplatin therapy as first-line chemotherapy for clear cell
adenocarcinoma of the ovary: a JGOG study. Int J Gynecol Cancer.
20:240–247. 2010. View Article : Google Scholar : PubMed/NCBI
|
7.
|
Shimada M, Kigawa J, Ohishi Y, et al:
Clinicopathological characteristics of mucinous adenocarcinoma of
the ovary. Gynecol Oncol. 113:331–334. 2009. View Article : Google Scholar : PubMed/NCBI
|
8.
|
Schreiber RD, Old LJ and Smyth MJ: Cancer
immunoediting: integrating immunity’s roles in cancer suppression
and promotion (Review). Science. 331:1565–1570. 2011.PubMed/NCBI
|
9.
|
Nelson BH: The impact of T-cell immunity
on ovarian cancer outcomes (Review). Immunol Rev. 222:101–116.
2008. View Article : Google Scholar : PubMed/NCBI
|
10.
|
Kusuda T, Shigemasa K, Arihiro K, et al:
Relative expression levels of Th1 and Th2 cytokine mRNA are
independent prognostic factors in patients with ovarian cancer.
Oncol Rep. 13:1153–1158. 2005.PubMed/NCBI
|
11.
|
Marth C, Fiegl H, Zeimet AG, et al:
Interferon-gamma expression is an independent prognostic factor in
ovarian cancer. Am J Obstet Gynecol. 191:1598–1605. 2004.
View Article : Google Scholar : PubMed/NCBI
|
12.
|
Seike M, Yanaihara N, Bowman ED, et al:
Use of a cytokine gene expression signature in lung adenocarcinoma
and the surrounding tissue as a prognostic classifier. J Natl
Cancer Inst. 99:1257–1269. 2007. View Article : Google Scholar : PubMed/NCBI
|
13.
|
Kurman RJ and Shih IeM: Molecular
pathogenesis and extraovarian origin of epithelial ovarian cancer -
shifting the paradigm. Hum Pathol. 42:918–931. 2001. View Article : Google Scholar : PubMed/NCBI
|
14.
|
Bustin SA: Absolute quantification of mRNA
using real-time reverse transcription polymerase chain reaction
assays. J Mol Endocrinol. 25:169–193. 2000. View Article : Google Scholar : PubMed/NCBI
|
15.
|
Li N, Grivennikov SI and Karin M: The
unholy trinity: inflammation, cytokines, and STAT3 shape the cancer
microenvironment. Cancer Cell. 12:429–431. 2011. View Article : Google Scholar : PubMed/NCBI
|
16.
|
Itamochi H, Kigawa J and Terakawa N:
Mechanisms of chemoresistance and poor prognosis in ovarian clear
cell carcinoma (Review). Cancer Sci. 99:653–658. 2008. View Article : Google Scholar : PubMed/NCBI
|
17.
|
Tsiatas ML, Gyftaki R, Liacos C, et al:
Study of T lymphocytes infiltrating peritoneal metastases in
advanced ovarian cancer: associations with vascular endothelial
growth factor levels and prognosis in patients receiving
platinum-based chemotherapy. Int J Gynecol Cancer. 19:1329–1334.
2009. View Article : Google Scholar
|
18.
|
Tothill RW, Tinker AV, George J, et al:
Novel molecular subtypes of serous and endometrioid ovarian cancer
linked to clinical outcome. Clin Cancer Res. 14:5198–5208. 2008.
View Article : Google Scholar : PubMed/NCBI
|
19.
|
Anglesio MS, George J, Kulbe H, et al:
IL6-STAT3-HIF signaling and therapeutic response to the
angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin
Cancer Res. 17:2538–2548. 2011. View Article : Google Scholar : PubMed/NCBI
|
20.
|
Yamaguchi K, Mandai M, Oura T, et al:
Identification of an ovarian clear cell carcinoma gene signature
that reflects inherent disease biology and the carcinogenic
processes. Oncogene. 29:1741–1752. 2010. View Article : Google Scholar : PubMed/NCBI
|
21.
|
Hong DS, Angelo LS and Kurzrock R:
Interleukin-6 and its receptor in cancer: implications for
translational therapeutics (Review). Cancer. 110:1911–1928. 2007.
View Article : Google Scholar : PubMed/NCBI
|
22.
|
Nilsson MB, Langley RR and Fidler IJ:
Interleukin-6, secreted by human ovarian carcinoma cells, is a
potent proangiogenic cytokine. Cancer Res. 65:10794–10800. 2005.
View Article : Google Scholar : PubMed/NCBI
|
23.
|
Rabinovich A, Medina L, Piura B, Segal S
and Huleihel M: Regulation of ovarian carcinoma SKOV-3 cell
proliferation and secretion of MMPs by autocrine IL-6. Anticancer
Res. 27:267–272. 2007.PubMed/NCBI
|
24.
|
Jones S, Wang TL, Shih IeM, et al:
Frequent mutations of chromatin remodeling gene ARID1A in ovarian
clear cell carcinoma. Science. 330:228–231. 2010. View Article : Google Scholar : PubMed/NCBI
|
25.
|
Wiegand KC, Shah SP, Al-Agha OM, et al:
ARID1A mutations in endometriosis-associated ovarian carcinomas. N
Engl J Med. 363:1532–1543. 2010. View Article : Google Scholar : PubMed/NCBI
|
26.
|
Cullen SJ, Ponnappan S and Ponnappan U:
Catalytic activity of the proteasome fine-tunes Brg1-mediated
chromatin remodeling to regulate the expression of inflammatory
genes. Mol Immunol. 47:600–605. 2009. View Article : Google Scholar : PubMed/NCBI
|
27.
|
Wang Y, Niu XL, Qu Y, et al: Autocrine
production of interleukin-6 confers cisplatin and paclitaxel
resistance in ovarian cancer cells. Cancer Lett. 295:110–123. 2010.
View Article : Google Scholar : PubMed/NCBI
|
28.
|
Guo Y, Nemeth J, O’Brien C, et al: Effects
of siltuximab on the IL-6-induced signaling pathway in ovarian
cancer. Clin Cancer Res. 16:5759–5769. 2010. View Article : Google Scholar : PubMed/NCBI
|
29.
|
Coward J, Kulbe H, Chakravarty P, et al:
Interleukin-6 as a therapeutic target in human ovarian cancer. Clin
Cancer Res. 17:6083–6096. 2011. View Article : Google Scholar : PubMed/NCBI
|